SiBone (SIBN) Expected to Announce Earnings on Monday

Key Points

• SiBone is expected to report its Q1 2026 results after the market closes on Monday, May 11 (earnings call 4:30 PM ET); analysts forecast EPS of ($0.17) and revenue of $51.16 million.
• In the prior quarter SiBone beat estimates with EPS of ($0.04) on $56.35 million in revenue, but analysts still expect about ($1) EPS for the current fiscal year and $0 for next year; the stock has a market cap of $584.4 million and a one‑year range of $11.80–$21.89.
• Insiders have sold shares recently (167,360 shares worth ~$2.55M in the last three months) while institutions own ~98.11% of the stock; analysts’ views are mixed but the consensus rating is a Moderate Buy with a $24 price target.

SiBone (NASDAQ:SIBN - Get Free Report) is projected to post its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect SiBone to post earnings of ($0.17) per share and revenue of $51.1570 million for the quarter. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:30 PM ET.

SiBone (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.09. SiBone had a negative return on equity of 11.01% and a negative net margin of 9.41%.The company had revenue of $56.35 million for the quarter, compared to analysts' expectations of $56.26 million. On average, analysts expect SiBone to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

SiBone Stock Performance

SiBone stock opened at $13.21 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 8.55 and a quick ratio of 7.21. SiBone has a one year low of $11.80 and a one year high of $21.89. The stock has a market capitalization of $584.41 million, a PE ratio of -30.02 and a beta of 0.67. The business's fifty day moving average is $13.70 and its 200 day moving average is $16.23.

Insiders Place Their Bets

In other SiBone news, CFO Anshul Maheshwari sold 21,528 shares of the firm's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $15.37, for a total value of $330,885.36. Following the transaction, the chief financial officer directly owned 266,466 shares of the company's stock, valued at approximately $4,095,582.42. This trade represents a 7.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mika Nishimura sold 4,100 shares of the firm's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $13.83, for a total value of $56,703.00. Following the completion of the transaction, the director directly owned 32,716 shares in the company, valued at $452,462.28. The trade was a 11.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 167,360 shares of company stock valued at $2,545,552. 3.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Invesco Ltd. lifted its position in shares of SiBone by 18.5% during the 4th quarter. Invesco Ltd. now owns 55,715 shares of the company's stock valued at $1,099,000 after buying an additional 8,706 shares in the last quarter. Susquehanna Portfolio Strategies LLC lifted its position in shares of SiBone by 579.2% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 105,365 shares of the company's stock valued at $2,078,000 after buying an additional 89,851 shares in the last quarter. Tudor Investment Corp ET AL lifted its position in shares of SiBone by 0.6% during the 4th quarter. Tudor Investment Corp ET AL now owns 259,589 shares of the company's stock valued at $5,119,000 after buying an additional 1,557 shares in the last quarter. Man Group plc purchased a new position in shares of SiBone during the 4th quarter valued at about $965,000. Finally, Inspire Investing LLC purchased a new position in shares of SiBone during the 4th quarter valued at about $1,246,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. TD Cowen increased their price objective on SiBone from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Tuesday, February 24th. Wall Street Zen cut SiBone from a "buy" rating to a "hold" rating in a research report on Saturday, April 18th. Finally, Truist Financial dropped their target price on SiBone from $24.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, April 15th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, SiBone presently has a consensus rating of "Moderate Buy" and a consensus price target of $24.00.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.